[to the editor:]{.smallcaps} In his outstanding article, Jakovac ([@B7]) highlighted the relevance of vitamin D in coronavirus disease (COVID-19) context. In fact, this seems an important metabolic explanation for the higher vulnerability for severe forms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the patients with obesity and hypertension or older patients. There are no published intervention studies to prove that vitamin D supplementation could help with COVID-19 outcomes. However, our group specializing in phenylketonuria (PKU; McKusick \#261600) are unaware of any reported deaths from COVID-19 in this patient group. Could it be that patients with PKU are spared from COVID-19 severe outcomes? A proof of concept that vitamin D status could effectively help infected individuals with the new coronavirus might be fostered from this observation.

In fact, for many patients with PKU, a phenylalanine-restricted diet remains the only management strategy, despite emerging pharmacological treatments. It is established that stringent dietary treatment accomplishes near-normal outcomes ([@B14]). Dietary management involves a controlled phenylalanine intake, supplemented with a low phenylalanine protein substitute, usually containing micronutrients ([@B12]). Initially, nutritional requirements were not fully understood, and unpalatable medical formulas without rigorous supplementation led to nutritional deficiencies ([@B10]). In recent years, the quality of dietary treatment has considerably improved, protein substitutes are fortified with micronutrients to meet requirements, and there are few reports of micronutrient inadequacy in PKU ([@B8]). Balanced nutrition is required for optimal cell function with vitamins A, B~6~, B~12~, C, D, E, folate, trace elements, and essential fatty acids important and complementary in supporting the immune system ([@B1]).

Although vitamin D deficiency is common in the general population, several recent studies reported good or improved vitamin D status in patients with PKU, dependent on the amount of protein substitute being consumed. A patient, taking 60 g/day protein equivalent from protein substitute will receive around 13 to 30 µg/day of vitamin D compared with a requirement varying between 10 to 15 µg/day for adults ([@B3], [@B15]). In the United Kingdom, Daly et al. ([@B2]) reported median 25-hydroxy-vitamin D levels above 80 nmol/L in 50 PKU diet-treated patients aged 5 to 16 yr. At the end of 1 yr intervention, no patient had a vitamin D concentration of ≤50 nmol/L. Also, in adults with PKU, the vitamin D intake was significantly higher in diet-adherent compared with nonadherent patients (25.8 ± 8.96 vs. 4.16 ± 5.31 μg/day, respectively; *P* \< 0.001) ([@B6]). Thiele et al. ([@B16]) showed in patients with PKU that vitamin D intake decreased to less than requirements when protein substitute intake was lowered as a consequence of pharmacological treatment. A recent, retrospective study from early treated adults with PKU patients from 17 European centers highlighted a low number (*n* = 32 of 173) of patients with low vitamin D status (25-OH vitamin D \<50 nmol/L) ([@B9]). Experience from Portugal comparing a group of patients with PKU with healthy controls showed vitamin D inadequacy was more prevalent in the control group ([@B13]).

Although there is no direct evidence that vitamin D will prevent or treat COVID-19, vitamin D may help ([@B5]). Data from the University of Turin, Italy, indicated a high prevalence of hypovitaminosis D in hospitalized patients with COVID-19 ([@B4]). In PKU, associated with the nutrient supplementation in protein substitutes, it is possible that satisfactory vitamin D status offers protection against COVID-19. This, of course, is speculation, and COVID-19 incidence in patients with PKU within and between countries is not reported. To understand if nutritional status may influence acute respiratory infection rate in COVID-19, it seems important to study the occurrence of COVID-19 in adolescent and adult patients with PKU and compare outcome with their treatment status. In addition, individual susceptibility to vitamin D deficiency and dose response of supplementation strategies should be based on assessing single nucleotide polymorphisms (SNPs) in vitamin D metabolism ([@B11], [@B17]).
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